Senores Pharmaceuticals Limited has successfully completed the first phase of its strategic acquisition of Apnar Pharma Private Limited. The company announced on January 16, 2026, that it has acquired 75% equity stake in the target company, marking a significant milestone in the ₹91.00 crore acquisition deal initially announced in December 2025.

Acquisition Completion Details

The pharmaceutical company has completed the acquisition of 56,63,804 equity shares from existing shareholders of Apnar Pharma Private Limited. This transaction represents the first tranche of the two-phase acquisition structure outlined in the original Share Purchase Agreement.

Original Acquisition Framework

The acquisition was initially approved by the Management Committee of the Board of Directors on December 15, 2025, with a total enterprise value of ₹91.00 crores. The deal structure combines strategic value creation with phased implementation to ensure smooth integration.

Manufacturing Facility Assets

The acquired facility in Jambusar, Gujarat represents a state-of-the-art pharmaceutical manufacturing operation that commenced in 2021. The facility received USFDA approval in September 2022 and maintains multiple international regulatory certifications including UK-MHRA and Health Canada approvals.

Production Capabilities

The facility demonstrates significant production capabilities across multiple dosage forms with substantial expansion potential. Current operations serve regulated markets including the US, UK, and Canada.

Strategic Value and Market Access

The acquisition provides immediate access to regulated markets beyond Senores Pharmaceuticals' current US presence. According to Swapnil Shah, Promoter Managing Director, the facility will enable manufacturing of select US products from India, improving operational leverage and supporting margin expansion.

Key strategic benefits include enhanced market access across regulated territories, revenue and cost synergies through cross-selling, backward integration via in-house manufacturing, and expansion of product portfolio. The deal includes 5 approved ANDAs representing a total addressable market exceeding $700 million.

Regulatory Compliance

The transaction has been disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited and National Stock Exchange of India Limited about the completion of the first tranche, ensuring full compliance with regulatory requirements.

Senores Pharmaceuticals has announced the regulatory approval and commercial launch of Deferiprone Tablets USP in 500mg and 1000mg strengths for the United States market. The pharmaceutical company disclosed this development through a media release filed under Regulation 30 of SEBI listing requirements.

Product Launch and Market Partnership

The newly launched Deferiprone Tablets are bioequivalent and therapeutically equivalent to Ferriprox Tablets manufactured by Chiesi USA, Inc. The product will be marketed and distributed by Dr. Reddy's Laboratories Inc. in the US market, representing a strategic partnership for market penetration.

Market Opportunity and Strategic Focus

According to Symphony data, Deferiprone Tablets in both brand and generic forms generated approximately $70.00 million in US sales for the twelve months ending in recent data. Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, emphasized the strategic importance of this launch, stating it advances the company's growth through entry into a limited-competition product segment.

The launch aligns with Senores' strategic focus on identifying and entering niche, under-penetrated generic formulations that present opportunities to serve unmet healthcare needs. This approach positions the company in specialized therapeutic areas with reduced competitive pressure.

Company Portfolio and Manufacturing Capabilities

Senores Pharmaceuticals operates as a global, research-driven pharmaceutical company with extensive manufacturing and development capabilities. The company's current portfolio encompasses significant regulatory approvals and pipeline products across multiple markets.

Manufacturing Infrastructure

The company maintains a robust manufacturing infrastructure with facilities strategically located to serve both regulated and emerging markets. Senores operates two formulation manufacturing facilities - one USFDA-approved facility in Atlanta, US, which is DEA and TAABAA compliant for controlled substances, and another WHO-GMP approved facility in Chhatral, Ahmedabad, India.

The company also operates two API manufacturing facilities in India, located in Chhatral and Naroda near Ahmedabad, with regulatory approvals from over 10 countries. Additionally, Senores maintains strong research and development capabilities across three R&D sites to drive its differentiated product portfolio development.